A proposed move to allow pharmacists to substitute cheaper biosimilar insulins for originator brands could harm patients, Diabetes Australia has warned. In a submission to the National Health Amendment (Pharmaceutical Benefits) Bill 2015 the organisation said it was strongly opposed to “a flagging” of pharmacy level substitution of any biosimilar insulin product. Unlike generics, biosimilars were different ...
Type 1 diabetes
Concern over biosimilar insulin substitution
By Nicola Garrett
23 Jun 2015